PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor (Chk1 inhibitor). As per the agreement, the Taiwanese pharma company will finance the investigational new drug (IND) enabling studies for SOL-578. Sentinel Oncology is a drug discovery company engaged in […]
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According to Center Laboratories, the orally administered small molecule drug candidate delivered significant reductions in glycated hemoglobin (HbA1c) in comparison to the placebo group. The phase 2 clinical trial is a […]
Continue reading …TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of inherited Epidermolysis Bullosa (EB). The phase 2 trial of AC-203 is a double-blind, intra-individual comparison, proof-of-concept clinical trial and will feature patients as young as two years of age. The […]
Continue reading …